ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

elismetrep

Also written as “MT-8554”, “Elismetrep” and “MT-8554 low dose”.

Its studies are mostly in Migraine Disorders · Hot Flashes, led by 2 companies.

Drug pageElismetrep: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 29, 201714 company-led studies, 3 open or runningNext primary completion: Feb 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tanabe Pharma100 open or runningphase 2since May 29, 2017Apr 16, 2015none ahead
TriGemX Bioits history only43 open or runningphase 3since Jun 9, 2026Feb 21, 2025Feb 2027phase 3 · NCT07645924

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Tanabe Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Apr 16, 2015First study: phase 1 study in HealthyFirst studyNCT02429102 · 135 enrolled · United Kingdom
  2. Aug 16, 2015Phase 1 study in HealthyNCT02536209 · 20 enrolled · United Kingdom
  3. Feb 3, 2016Phase 1 study in HealthyNCT02675309 · 28 enrolled · United Kingdom
  4. Jun 14, 2016Phase 1 study in Vasomotor SymptomsNCT02803268 · 24 enrolled · Germany
  5. May 29, 2017Phase 2 study in Painful Diabetic Peripheral NeuropathyNCT03172598 · 61 enrolled · Germany, Hungary, Poland
  6. Sep 20, 2017Phase 2 study in Menopause Hot FlashesNCT03291067 · 375 enrolled · United States
  7. Nov 29, 2017Phase 1 study in Healthy VolunteerNCT03381404 · 6 enrolled · United Kingdom
  8. Dec 9, 2017Named elismetrepINNProposed as its International Nonproprietary Name in WHO's List 118 · before, MT-8554
  9. Feb 28, 2018Phase 1 study in Healthy VolunteerNCT03471130 · 48 enrolled · United Kingdom
  10. Mar 29, 2018Phase 2 study in Vasomotor Symptoms (VMS)NCT03541200 · 190 enrolled · United States
  11. Oct 18, 2021Phase 2 study in Painful Diabetic Peripheral NeuropathyNCT05123196 · 156 enrolled · Japan

TargetBeta

TRPM8 →read by rule
“Transient receptor potential cation channel subfamily M member 8 inhibitor”ChEMBL 37, by rule

Studies

All 10 Tanabe Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05123196Painful Diabetic Peripheral Neuropathy · Japan2CompletedNov 1, 2022156
NCT03541200Vasomotor Symptoms (VMS) · United States2CompletedNov 15, 2019190
NCT03471130Healthy Volunteer · United Kingdom1CompletedOct 19, 201848
NCT03381404Healthy Volunteer · United Kingdom1CompletedJan 29, 20186
NCT03291067Menopause Hot Flashes · United States2CompletedOct 19, 2018375
NCT03172598Painful Diabetic Peripheral Neuropathy · Germany, Hungary, Poland2CompletedAug 8, 201861
NCT02803268Vasomotor Symptoms · Germany1CompletedJan 201724
NCT02675309Healthy · United Kingdom1CompletedMar 201628
NCT02536209Healthy · United Kingdom1CompletedNov 201520
NCT02429102Healthy · United Kingdom1CompletedNov 2015135

How it is read

Names in the registry

  • “MT-8554”, 4 entries
  • “Elismetrep”, 3 entries
  • “MT-8554 low dose”, 3 entries
  • “MT-8554 high dose”, 3 entries
  • “MT-8554 middle dose”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.